Mylan shares slide after warning of hit to revenue
Generic drugmaker Mylan NV said on Tuesday reevaluation of its portfolio of medicines will continue next year and cautioned of a hit to revenue, and its shares nearly 6%.
Generic drugmaker Mylan NV said on Tuesday reevaluation of its portfolio of medicines will continue next year and cautioned of a hit to revenue, and its shares nearly 6%.